It has been reported that the prevalence of FGFR3-TACC3 fusion in bladder cancer is 2–3% [20–22] and erdafitinib was the first orally effective FGFR antagonist approved by the FDA (2019) for the treatment of the urothelial carcinoma [23]. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.